Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor

US10160744B2 · kind B2 · utility

Assignee

• Abb Vie Deutschland Gmbh & Co. KG · DE

Inventors

• Hervé Geneste · Schifferstadt, DE
• Andreas Haupt · Ludwigshafen, DE
• Frauke Pohlki · Wiesbaden, DE
• Ana-Lucia Relo · Ludwigshafen, DE
• Liliane Unger · Ludwigshafen, DE
• Karsten Wicke · Ludwigshafen, DE

Key dates

• Filing date: Mar 14, 2017
• Grant date: Dec 25, 2018
• Expiry date: Mar 14, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.